Oppenheimer initiated coverage of Opus Genetics (IRD) with an Outperform rating and $10 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics files to sell 7.37M shares of common stock for holders
- Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst
- Ocuphire’s Nyxol Presbyopia Trial Nears Data: What Investors Should Watch
- Opus Genetics price target raised to $10 from $8 at Wedbush
- Buy Rating on Opus Genetics Driven by Advancing Gene Therapy Pipeline, Near‑Term Clinical Catalysts, and Solid Cash Runway